指南与共识肿瘤 PET/CT骨显像与常规 SPECT

全身68Ga-PSMA-11 PET/CT检测前列腺癌骨转移:对骨扫描指南的潜在影响

Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines.
指南 / 共识 · J Nucl Med · 2019-09-20

该回顾性分析纳入388例前列腺癌患者,评估血清PSA水平与全身68Ga-PSMA-11 PET/CT检出骨转移的关系。结果显示骨转移发生率随PSA水平升高而增加(<10 ng/mL为21%,10-20 ng/mL为41%,≥20 ng/mL为41%,P<0.001),且全身采集仅对0.26%患者的管理产生影响。作者建议重新审视现有骨评估指南。

要点

  • 低血清PSA水平患者中68Ga-PSMA-11 PET/CT仍可检出骨转移。
  • 骨转移发生率与PSA水平正相关,与NCCN风险评分无关。
  • 全身采集(头顶至足趾)仅对0.26%患者的管理产生影响。

核心结论

  • 68Ga-PSMA-11 PET/CT评估的骨转移在低血清PSA水平患者中仍常见,现有骨评估指南应重新审视。
  • 全身采集(头顶至足趾)可发现额外骨病灶,但未显著影响患者管理。

研究设计与样本

  • 回顾性分析388例前列腺癌患者,来自5项前瞻性研究(NCT02940262、NCT03368547、NCT03042312、NCT04050215、NCT03515577)。
  • 所有患者接受头顶至足趾的68Ga-PSMA-11 PET/CT采集,用于初始分期(93/388,24%)、生化复发定位(225/388,58%)或系统治疗前/中转移性疾病再分期(70/388,18%)。
  • 采集时间为2017年9月至2018年5月。

主要发现

  • 321/388(83%)患者68Ga-PSMA-11检查阳性。
  • 105/388(27%)患者发现PSMA阳性骨病灶,发生率与血清PSA水平正相关(<10 ng/mL为21%;10-20 ng/mL为41%;≥20 ng/mL为41%;P<0.001)。
  • 该关联在初始分期、生化复发和再分期M1三种指征中均维持。
  • 骨转移最常见于再分期M1,其次为生化复发和初始分期。
  • 骨转移发生率与NCCN风险评分无显著关联(P=0.22)。

关键数值与推荐

  • 血清PSA水平分类:<5、5-10、10-20和>20 ng/mL。
  • 骨转移发生率:<10 ng/mL为21%,10-20 ng/mL为41%,≥20 ng/mL为41%(P<0.001)。

临床怎么用

  • 68Ga-PSMA-11 PET/CT可在低血清PSA水平患者中检出骨转移,提示现有骨评估指南可能需要更新。
  • 全身采集(头顶至足趾)可发现额外骨病灶,但对患者管理影响有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to determine the relationship between serum prostate-specific antigen (PSA) level categories (<5, 5-10, 10-20, and >20 ng/mL) and the incidence of bone metastases detected by total-body 68Ga-prostate-specific membrane antigen (PSMA)-11 PET/CT and to assess if expanding the 68Ga-PSMA-11 PET/CT imaging field to include the vertex and lower extremities (total-body acquisition) affects bone metastasis detection rates and patient management. Methods: This was a retrospective analysis of 388 prostate cancer patients enrolled in 5 prospective studies (NCT02940262, NCT03368547, NCT03042312, NCT04050215, and NCT03515577). All underwent 68Ga-PSMA-11 PET/CT scans acquired from vertex to toes for primary staging (n = 93/388, 24%), biochemical recurrence (BCR) localization (n = 225/388, 58%), or restaging metastatic disease (M1) before or during systemic therapy (n = 70/388, 18%) between September 2017 and May 2018. Results: In total, 321 of 388 patients (83%) had a positive 68Ga-PSMA-11 study. PSMA-positive bone lesions were found in 105 of 388 (27%) patients, with an incidence that was positively associated with serum PSA level (<10 ng/mL, 21%; 10-20 ng/mL, 41%; ≥20 ng/mL, 41%; P < 0.001). This association was maintained for all 3 indications: initial staging, BCR, and restaging M1. Bone metastases occurred most frequently in restaging M1, followed by BCR and initial staging. Bone metastasis incidence was not significantly associated with National Comprehensive Cancer Network risk score (P = 0.22). The average number of PSMA-positive regions also increased with serum PSA level (P < 0.001). Eighteen of 388 (5%) and 18 of 388 (5%) had lesions above the superior orbital ridge and below the proximal third of the femur, respectively. There was only 1 of 388 patients (0.26%) in whom the total-body PET acquisition had an impact on management. Conclusion: Bone metastases as assessed with 68Ga-PSMA-11 PET/CT are prevalent even in patients with low serum PSA levels. Therefore, current guidelines for bone assessments in prostate cancer patients should be revisited because 68Ga-PSMA-11 PET/CT may provide additional information for accurate bone staging at low serum PSA levels. Including the total body (from vertex to toes) in 68Ga-PSMA-11 PET/CT imaging revealed additional bone lesions in 6% of patients, but without significantly affecting patient management.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Pomykala KL, Czernin J, Grogan TR, et al. Total-Body 68Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: Potential Impact on Bone Scan Guidelines. J Nucl Med. 2019. PMID: 31541035. doi:10.2967/jnumed.119.230318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。